Skip to content

A Post-Market Clinical Follow-up Study to Investigate the Usability of the CollaGUARD Adhesion Barrier following Hysteroscopic Adhesiolysis

A Post-Market Clinical Follow-up Study to Investigate the Usability of the CollaGUARD Adhesion Barrier following Hysteroscopic Adhesiolysis - INN-CG-001

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41131
Enrollment
10
Registered
2014-10-08
Start date
2014-09-14
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adherence of internal walls of the uterus intrauterine adhesions (IUA)

Interventions

None listed

Sponsors

Innocoll Technologies
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Be a female >=18 and

Exclusion criteria

Exclusion criteria: - Be pregnant or having a suspected molar pregnancy, lactating, or planning to become pregnant at any time during the study - Be a female of childbearing potential not using a reliable means of contraception - Has suffered or currently suffers from a gynaecological malignancy - Has a current genital infection - Has a known or suspected hypersensitivity to collagen - Has a known or suspected increased risk of infections (due to e.g. (auto)immune diseases or taking medications influencing infection risk) - Has undergone a previous hysteroscopic surgery (such as removal of fibroids) - Has a condition or be in a situation that, in the Investigator*s opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject*s participation in the study - No adhesion formation present in the uterus - Severe adhesion formation which cannot be removed in one procedure - Has a condition or be in a situation which could only be determined during the hysteroscopic procedure that, in the Investigator*s opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject*s participation in the study

Design outcomes

Primary

MeasureTime frame
The primary endpoint of this clinical investigation is to determine the usability of the use of CollaGUARD in hysteroscopic adhesiolysis. Safety shall be assessed by means of recording serious adverse events. The safety endpoint of this trial is freedom from unexpected serious device related adverse events during the complete study period.

Secondary

MeasureTime frame
The secondary endpoints of this clinical investigation are: - The number of de novo adhesions and adhesion reformations - Change in severity of the adhesions based on the ESGE and mAFS IUA classification scale at all follow-up visits - Product positioning and degradation level at each follow-up visit

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)